Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Peptide Administration Routes — Compared

Different administration routes change a peptide's bioavailability, time to peak, plasma half-life, and risk profile. This page describes how — and why each route carries its own safety considerations. It is not an instruction page.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Peptide drugs have historically been dominated by injectable administration because most peptides are poorly orally bioavailable — the gastric environment and intestinal proteases degrade them rapidly, and the intestinal epithelium has limited permeability for molecules of their size. A number of route-of-administration innovations have widened the options for specific compounds; understanding the differences is part of reading the peptide research literature responsibly.

This page is descriptive — it explains how routes differ as reported in published research. It does not instruct self-administration. PeptideStacks does not provide injection technique, syringe selection, or any step-by-step administration guidance. See: responsible information policy, medical disclaimer, why injectable route research is higher risk.

Subcutaneous (SC)

The most common research route for peptides. SC injection delivers material into the loose connective tissue beneath the skin, where it absorbs into systemic circulation over minutes to hours depending on the molecule's lipophilicity, size, and any fatty-acid conjugation. SC administration is the basis for most marketed peptide medicines — insulin, semaglutide, tirzepatide, tesamorelin — and for almost all published research-context dosing.

  • Pharmacokinetics: moderate Cmax, longer Tmax than IV; for fatty-acid-conjugated peptides the absorption phase dominates the half-life and produces effectively flat plasma profiles with weekly dosing (semaglutide, tirzepatide).
  • Bioavailability: typically 50–90% for properly formulated peptides.
  • Risk profile: sterility failure leads to localised abscess or systemic infection. Endotoxin contamination can produce fever and inflammatory response. Site rotation prevents lipodystrophy with chronic dosing.

Intramuscular (IM)

Delivery into skeletal muscle tissue. Used for some depot formulations (e.g. testosterone esters, depot leuprolide) and occasionally for peptide research. Absorption is typically faster than SC due to better perfusion, but the difference is modest for most peptides.

  • Pharmacokinetics: faster Tmax than SC, similar bioavailability.
  • Bioavailability: high for water-soluble peptides; depot oil-based formulations create distinct kinetics.
  • Risk profile: sciatic nerve injury at the gluteal site if administered without anatomical knowledge; haematoma risk in patients on anticoagulants; intravascular injection a recognised hazard.

Intravenous (IV)

Direct delivery into systemic circulation, used principally in clinical settings (hospital, infusion clinic) and in pharmacokinetic study contexts. Bypasses all absorption phases; achieves immediate Cmax. Used in published research for SS-31 (elamipretide) single-dose pharmacology and for some thymic peptides in clinical trial contexts.

  • Pharmacokinetics: immediate Cmax; full plasma half-life is observed as elimination half-life.
  • Bioavailability: by definition 100%.
  • Risk profile: highest of any route. Air embolism, intravascular contamination, anaphylaxis with no time-buffer to respond. Strictly clinical-setting administration in any responsible context.

Intranasal (IN)

Delivery via the nasal mucosa, used for peptides where the molecular weight and lipophilicity permit absorption. The published peptide literature uses IN administration most often for compounds targeting the central nervous system — Semax, Selank, Pinealon — because the olfactory and trigeminal pathways provide partial nose-to-brain delivery, bypassing the blood-brain barrier to a limited extent.

  • Pharmacokinetics: rapid onset (minutes), short duration, modest plasma bioavailability for most peptides.
  • Bioavailability: typically 5–30% systemically; nose-to-brain transfer is debated and likely modest.
  • Risk profile: local mucosal irritation, sneezing, occasional epistaxis. Lower systemic risk than injection routes.
  • Glossary: intranasal administration.

Oral

The route most desired and most difficult for peptide pharmacology. The native intestinal epithelium and proteolytic environment exclude almost all peptides. Two notable exceptions have reached the clinic:

  • Oral semaglutide (Rybelsus) — formulated with the absorption enhancer SNAC, which transiently disrupts the gastric epithelium and allows partial systemic uptake. Bioavailability is ~1%, but the molecule's potency makes the formulation clinically meaningful.
  • BPC-157 oral — claimed to be stable in gastric fluid (it was originally identified as a fragment of body protection compound from gastric juice) and is sometimes investigated orally in rodent GI-injury models. Human oral PK is poorly characterised.

For peptides that are not specifically formulated for oral delivery, oral administration is pharmacologically essentially inert — the molecule does not reach systemic circulation in any clinically meaningful concentration.

Topical

Delivery via cutaneous application. Used principally for cosmetic and dermal-repair contexts (GHK-Cu) where the formulation permits limited percutaneous absorption. Systemic exposure is minimal for most peptides via this route.

Why route choice matters for evidence interpretation

A peptide studied at 250 μg subcutaneous twice daily in a rodent injury model has a very different pharmacological profile from the same peptide delivered intravenously at the same total dose. When reading a peptide study, the route is part of the dose. Where an online source describes “BPC-157 dosing” without specifying route, the claim is incomplete — and frequently a sign that the underlying paper has not been read carefully.

What this site does not provide

  • Injection technique, site selection, or syringe specifications.
  • Reconstitution arithmetic intended for human use (see lab documentation unit converter for the chemistry-only helper).
  • Personalised route selection for any indication.
  • Acquisition or sourcing guidance for any compound by any route.

Glossary